That's a great problem to have....wondering how nicely Vascepa and Apabetalone will play with one another. It's actually not too far fetched that they would be complimentary. The Kaplan-Meier curves for Vascepa in REDUCE-IT didn't start separating until about 2 years in for a median dosing period of about 5 years, whereas BETonMACE will have a median dosing period closer to two years. Of course, REDUCE-IT was a mix of primary and secondary prevention, and probably very few patients for secondary prevention with an ACS event within 90 days. Apabetalone, if BETonMACE succeeds, will be the first CVOT to elicit benefit in high risk recent ACS diabetic patients. Vascepa hasn't been tested in this BETonMACE population, and apabetalone hasn't been tested in the REDUCE-IT population. But if apabetalone proves 3-point MACE reduction in high risk diabetic recent ACS patients, that would arguably be the go to standard of care for secondary prevention in this population.

BearDownAZ